Secondary Logo

Journal Logo

Lactobacillus reuteri Tablets Can Suppress Helicobacter pylori Infection

A Double-Blind, Randomised, Placebo-Controlled Cross-Over Clinical Study


Imase, Kyoto; Tanaka, Akifumi; Tokunaga, Kengo; Sugano, Hajime; Takahashi, Shin'ichi

American Journal of Gastroenterology: September 2005 - Volume 100 - Issue - p S55–S56
Supplement Abstracts Submitted for the 70th Annual Scientific Meeting of the American College of Gastroenterology: STOMACH

Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.

Purpose: The aim was to investigate the effect of Lactobacillus reuteri strain SD2112 Tablets (Reuterina®), in suppressing on H. pylori urease activity and to use the urea breath test (UBT) as a marker for burden of infection.

Methods: Assessment of UBT and H. pylori density, 33 H. pylori-positive patients were obtained gastric biopsy specimens by upper gastrointestinal endoscopy. The correlation between UBT and H. pylori density was investigated. The individual UBT values were established for each patient. The patients were divided into three groups according to H. pylori density: Group I (low density group), Group II (moderate density group), and Group III (high density group). The individual UBT values were then correlated to the established H. pylori quantity.

Method: 2 Assessment of suppressive effect of L. reuteri on H. pylori urease activity asymptomatic 40 volunteers with an UBT value higher than 15‰ were randomly allocated to four groups, as follows. Subjects in Group A received active treatment for 4 weeks (period 1) and placebo treatment for the following 4 weeks (period 2), in Group B received the study treatment in the reverse order. In GroupC received placebo and in GroupD consisted of volunteers that had a negative UBT received active treatment, for the full 8 weeks.

Results: 1. UBT values were 11.6 ± 2.0‰, 22.1 ± 2.6‰ and 35.4 ± 7.6‰ in Groups I, II and III, respectively, showing the UBT value to increase significantly (I vs. II: p < 0.01 and I vs. III: p < 0.05) according to H. pylori density.

Results: 2 There were significant differences in the decrease in UBT value before versus after medication in Group A and Group B. Moreover, in Group A, lower UBT value was maintained until the end of the full 8-week period. The overall rate of decrease in the UBT value due to medication with L. reuteri Tablets was 69.7 ± 4.0% (p < 0.05).

Conclusions: Administraion of L. reuteri Tablets significantly decreased UBT values in H. pylori-positive subjects, demonstrating that L. reuteri suppresses H. pylori urease activity and H. pylori density.

© The American College of Gastroenterology 2005. All Rights Reserved.